Jessica Grossman

Dr. Grossman joined the Board of Directors in April 2018. Dr. Grossman currently serves as the CEO of IgGenix, a company developing first-in-class therapies for people limited by food allergies and other severe allergic conditions. From 2015 to 2020, Dr. Grossman served as CEO of Medicines360, a global non-profit women’s health pharmaceutical company that pioneered the development of the FDA approved contraceptive IUS LILETTA® (levonorgestrel-releasing intrauterine system) and successfully partnered that program with Allergan, a global pharmaceutical company. From 2013 to 2014, Dr. Grossman served as President and Founding CEO of Sense4Baby where she led the company through a successful acquisition following FDA clearance, CE mark, and post-approval commercialization. Dr. Grossman served as a Medical Director at Ethicon Endo-Surgery, part of the Johnson & Johnson family of companies, from 2010 to 2013. From 2008 to 2010, Dr. Grossman was the Founder and CEO of JG Limited LLC, a consulting company providing services to medical technology companies and non-profit organizations in the areas of clinical and commercial strategy. From 2005 to 2008, Dr. Grossman was Founder and President of Gynesonics, an early-stage medical device company focused on minimally invasive solutions for women’s health which developed the first intrauterine ultrasound-guided radiofrequency ablation device for fibroid tumors. Dr. Grossman holds numerous patents, has published several peer-reviewed articles and conducted research at the Beth Israel Deaconess Medical Center, one of the teaching hospitals of Harvard Medical School. Dr. Grossman received her MD from Thomas Jefferson University, Jefferson Medical College.